Yes. The next step should be a **detailed Magniom Technical Specification & Architecture document**, but I would make it broader than a conventional software architecture spec.

Magniom sits at the intersection of **clinical decision support, neuroimaging, functional connectomics, evidence synthesis, TMS targeting, and potentially regulated medical-device software**. If we jump directly into coding the Next.js/Supabase application, we risk encoding scientific assumptions that later become difficult to change or validate.

The next document should therefore become the **canonical specification for the entire system**.

## Recommended next deliverable

# Magniom — Clinical, Scientific & Technical Architecture v1.0

Its purpose should be:

> **Define exactly how Magniom converts a patient's clinical phenotype, functional-connectomics MRI and published TMS circuit evidence into an auditable ranked slate of up to 3 primary and 2 additional TMS target candidates for specialist review.**

The fundamental architecture should remain:

**Clinical phenotype**
+
**Evidence-supported therapeutic circuits**
+
**Patient-specific functional connectomics**
+
**Target reliability**
+
**Cortical accessibility / electric-field modelling**
→
**Ranked candidate target slate**
→
**Specialist decision**
→
**Neuronavigation export**
→
**Treatment + outcomes**

Crucially, the clinician—not Magniom—makes the final prescription.

---

# What the specification should contain

I would structure it into approximately 20 major sections.

### 1. Product definition

Precisely define what Magniom is and is not.

**Magniom is:**

A clinician-facing TMS targeting decision-support platform.

**Magniom is not:**

* an autonomous prescribing system
* an MRI diagnostic system
* an automated psychiatric diagnosis engine
* a black-box AI treatment recommender
* a guarantee of optimal targeting

The core output is:

**Candidate Target Slate**

containing:

* Primary Target 1
* Primary Target 2
* Primary Target 3
* Alternative Target A
* Alternative Target B

but importantly:

> Magniom must be able to return fewer than five candidates when evidence is insufficient.

---

### 2. Clinical operating model

Define the entire clinical workflow:

**Patient → Assessment → Phenotype → Imaging → Connectome → Candidate Targets → Specialist Review → Prescription → Neuronavigation → Treatment → Outcomes**

We should specify what information exists at each stage and what gates must be passed before proceeding.

---

### 3. Initial indication scope

I recommend strongly resisting the temptation to start transdiagnostically.

**Magniom v1 should focus on:**

# Major depressive disorder ± anxious distress

because we have the strongest combination of:

* established TMS efficacy
* DLPFC evidence
* sgACC connectivity research
* symptom-specific depression circuitry
* prospective circuit-targeting data
* personalised connectivity trials
* enough contradictory evidence to build appropriate safeguards

Then extend sequentially:

**v2 — OCD**

**v3 — PTSD**

**v4 — chronic neuropathic pain**

**v5 — stroke / neurological rehabilitation**

Later:

brain injury, tinnitus and other indications.

---

### 4. Clinical phenotype ontology

This is one of the most important pieces.

We should explicitly model:

**Diagnosis**

↓

**Symptom domain**

↓

**Symptom severity**

↓

**Functional impairment**

↓

**Patient priority**

For depression, for example:

```text
Major depressive disorder

├── Dysphoria
├── Anhedonia
├── Low motivation
├── Anxious distress
├── Rumination
├── Cognitive slowing
├── Sleep disturbance
├── Somatic symptoms
└── Suicidal ideation
```

Each symptom gets:

* measurement
* severity
* confidence
* clinical priority
* evidence-linked circuits

We should avoid prematurely claiming every symptom has a validated TMS circuit.

---

### 5. Circuit evidence ontology

The scientific database should distinguish at least:

**Established treatment circuit**

**Prospectively validated symptom circuit**

**Replicated retrospective circuit**

**Single-study association**

**Mechanistic hypothesis**

This evidence hierarchy becomes fundamental to candidate ranking.

For example:

a beautiful individual connectivity abnormality should never automatically outrank a well-established depression target.

---

### 6. Evidence Knowledge Graph

This deserves its own formal schema.

Each evidence relationship should connect:

```text
Condition
↓
Symptom
↓
Circuit
↓
Cortical target
↓
Protocol
↓
Clinical outcome
↓
Evidence source
```

With metadata:

* study design
* N
* comparator
* target definition
* MNI coordinate
* atlas
* stimulation protocol
* coil
* outcome
* effect
* follow-up
* replication
* evidence grade
* limitations
* citation
* last reviewed

This database may ultimately become one of Magniom's most valuable assets.

---

### 7. MRI acquisition specification

This needs to be precise.

Define minimum acceptable acquisition for:

**T1 structural MRI**

and

**resting-state fMRI.**

The protocol should specify:

* field strength
* voxel size
* TR
* scan length
* head fixation
* eyes open/closed
* instructions
* motion limits
* sequence metadata

Given recent evidence about target instability, I would design Magniom around a **longer rs-fMRI acquisition than many historical personalised-targeting studies**.

A likely starting architecture could use:

**2 × resting-state runs**

rather than one short run.

That allows direct reliability testing.

---

### 8. Connectome pipeline

We should freeze an exact processing architecture.

For example:

**DICOM**

↓

**BIDS conversion**

↓

**T1 preprocessing**

↓

**surface reconstruction**

↓

**fMRI preprocessing**

↓

**motion censoring**

↓

**registration**

↓

**parcellation**

↓

**parcel time-series**

↓

**connectivity matrix**

↓

**normative deviation**

↓

**therapeutic circuit analysis**

↓

**candidate generation**

Everything must be versioned.

---

### 9. Functional-connectivity model

We need to decide exactly what Magniom computes.

Potential layers:

**whole-brain FC**

**network-level FC**

**seed-based therapeutic circuit FC**

**parcel-to-parcel FC**

**normative deviation**

**cross-atlas confirmation**

**split-half reliability**

This is where we need to decide how much of the Cingulum model to adopt versus redesign.

My inclination would be:

> use Cingulum's anomaly framework as one signal, not as the target-selection engine itself.

---

### 10. Normative connectome architecture

This will require careful thought.

We need:

* reference cohort
* acquisition harmonisation
* preprocessing consistency
* site/scanner adjustment
* age distribution
* quality thresholds
* normative model versioning

And most importantly:

Magniom should store **continuous deviation**, not simply:

**normal / abnormal**.

---

### 11. Target Candidate Engine

This is the central computational specification.

It should follow something like:

```text
Evidence-valid cortical candidate set
        ↓
Clinical symptom relevance
        ↓
Patient connectome concordance
        ↓
Reliability
        ↓
Anatomical accessibility
        ↓
Electric-field engagement
        ↓
Redundancy penalty
        ↓
Candidate slate
```

Importantly:

# Connectomics should rerank clinically defensible targets, not invent treatments from arbitrary abnormalities.

---

### 12. Ranking mathematics

Before coding, we should formally define the algorithm.

I would avoid a simplistic weighted score such as:

```text
0.25 evidence +
0.25 connectivity +
0.20 symptoms...
```

A multiplicative / gated model is safer.

Something conceptually like:

```text
Candidate Utility =
Clinical Evidence Gate
×
Phenotype Concordance
×
Connectome Concordance
×
Reliability
×
Stimulatability
```

Then:

**redundancy penalty**

and

**uncertainty penalty**

are applied.

This prevents:

an experimental target with spectacular FC abnormality from beating an established target merely because several weak scores add together.

---

### 13. Candidate diversity algorithm

The three primary targets should not simply be positions 1–3 in a list.

Magniom should optimise for:

# therapeutic coverage.

Example:

Candidate A:

anhedonia + dysphoria

Candidate B:

anhedonia + dysphoria

Candidate C:

anxiety + cognitive control

A and B may be individually ranked higher than C.

But the better three-target slate may include:

A + C + another orthogonal candidate

rather than three nearly identical nodes.

This becomes a constrained optimisation problem.

---

### 14. Target Reliability Engine

This is something I would elevate into a major Magniom differentiator.

For every target:

**scan reliability**

**connection reliability**

**split-half stability**

**cross-run stability**

**atlas stability**

**coordinate stability**

**pipeline stability**

The UI should display:

> **Target localisation stability: ±5.4 mm**

rather than pretending that a coordinate is exact.

This is scientifically much more honest.

---

### 15. Electric-field modelling

We should define whether Magniom v1 performs:

**distance-based accessibility**

or full:

**subject-specific E-field modelling.**

My recommendation:

MVP may start with cortical accessibility + coil-to-cortex distance.

But the canonical architecture should anticipate:

**SimNIBS-style E-field optimisation.**

Ultimately the target should include:

* cortical ROI
* coil centre
* coil orientation
* expected E-field
* target engagement
* off-target exposure

---

### 16. Target Explanation Engine

Each target should have a standard explanation object.

Example:

# Primary Target 2

**Parcel:** left 8Av
**Therapeutic objective:** anxious distress
**Evidence level:** B
**Patient-specific finding:** abnormal CEN–DMN connectivity
**FC reliability:** high
**Target stability:** 6.8 mm
**Cortical accessibility:** good
**E-field estimate:** favourable

### Why nominated

...

### Why it may be wrong

...

### Strongest supporting evidence

...

### Conflicting evidence

...

The last two fields are critical.

---

### 17. Human review model

Every candidate needs:

**Accept**

**Reject**

**Replace**

**Modify**

**Defer**

The clinician records why.

Example:

> Rejected because target overlaps previous non-responsive stimulation field.

That generates an extremely valuable future dataset:

**algorithm recommendation vs specialist decision vs clinical outcome.**

---

### 18. Supabase backend specification

We should formally design the schema.

Likely top-level tables:

```text
organisations
users
clinicians
patients

cases
assessments
diagnoses
symptoms
functional_goals

imaging_studies
imaging_series
processing_runs
qc_metrics

atlases
parcels
connectivity_matrices
connectivity_findings

circuits
evidence_sources
evidence_relations
protocols

target_candidates
target_slates
target_scores

clinician_reviews
target_decisions
neuronavigation_exports

treatment_courses
treatment_sessions
clinical_outcomes

algorithm_versions
pipeline_versions
audit_events
```

Supabase RLS should enforce strict:

**organisation → clinician → patient → case**

permissions.

---

### 19. Next.js frontend architecture

The UX should be designed around a clinical case.

Main navigation:

# Cases

Open case:

**Overview**

**Clinical phenotype**

**Imaging**

**Connectome**

**Target candidates**

**Target decision**

**Treatment**

**Outcomes**

The centerpiece should be a split workspace:

```text
Clinical phenotype
      |
      |       3D Brain
      |
Candidate evidence
```

Clicking any symptom highlights:

**associated circuits**

and then:

**patient-specific candidate targets.**

Clicking a target highlights:

**why it is relevant clinically and connectomically.**

---

### 20. Validation & regulatory architecture

This belongs inside the specification—not in a later document.

We should define:

**technical verification**

**imaging reproducibility**

**algorithm verification**

**expert concordance**

**retrospective validation**

**prospective silent validation**

**prospective clinician-assisted validation**

**randomised efficacy validation**

alongside:

* algorithm versioning
* audit logs
* change control
* clinical governance
* evidence review
* cybersecurity
* Australian privacy requirements
* anticipated TGA/SaMD implications

---

# Three companion specifications

I would not put absolutely everything into one giant document.

The ideal document suite is:

### Document 1 — Magniom Clinical & Scientific Specification v1.0

Defines:

**what the system is allowed to conclude.**

This is the most important document.

---

### Document 2 — Magniom Technical Architecture v1.0

Defines:

**how the software produces those conclusions.**

Includes:

Next.js, Supabase, neuroimaging workers, pipelines, schemas, APIs, security and deployment.

---

### Document 3 — Magniom Validation & Regulatory Plan v1.0

Defines:

**how we prove that the system is reliable enough to use.**

---

# Before implementation: one additional document

I would also create a compact:

# Magniom Canonical Target Data Specification

This defines a target independent of the UI.

For example:

```text
TargetCandidate
 ├── target_id
 ├── clinical_role
 ├── therapeutic_objective
 ├── anatomical_roi
 ├── hemisphere
 ├── atlas
 ├── parcel
 ├── subject_coordinate
 ├── mni_coordinate
 ├── circuit_membership
 ├── evidence_grade
 ├── evidence_sources
 ├── phenotype_concordance
 ├── connectivity_findings
 ├── normative_deviation
 ├── fc_reliability
 ├── spatial_stability
 ├── coil_distance
 ├── efield_engagement
 ├── redundancy_score
 ├── uncertainty
 ├── nomination_reason
 ├── counterarguments
 └── algorithm_version
```

Once that object is correct, the Supabase schema, targeting algorithm and frontend all become much easier to design correctly.

---

# Recommended development sequence

I would proceed in this exact order:

**1. Clinical & Scientific Specification**

↓

**2. Canonical Target Data Specification**

↓

**3. Technical Architecture**

↓

**4. Evidence Knowledge Graph schema**

↓

**5. Supabase data model**

↓

**6. Imaging/Connectome pipeline specification**

↓

**7. Target-ranking algorithm specification**

↓

**8. UX wireframe / clinician workflow**

↓

**9. Synthetic-data prototype**

↓

**10. Retrospective validation**

Only then:

# production clinical implementation.

The most important next step is therefore **not yet writing Next.js code**.

It is defining, with precision, exactly what Magniom means when it says:

> **“This is the strongest candidate target for this patient.”**

If that sentence can be mathematically, clinically and scientifically explained, the software architecture becomes straightforward. If it cannot, a polished frontend only conceals an unresolved scientific model.

So yes: **Magniom Clinical, Scientific & Technical Architecture v1.0 should be the next major deliverable**, with the clinical/scientific specification written first and the technical implementation derived from it.
